Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Article

Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial.

Eva Ciruelos Gil, MD, PhD

Eva Ciruelos Gil, MD, PhD

Atezolizumab (Tecentriq) in combination with trastuzumab (Herceptin) and vinorelbine (Navelbine) generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor (ER)­–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial (EudraCT 2020-000245-13; NCT04759248) presented at the 2023 ESMO Breast Cancer Annual Congress.1

Findings showed that evaluable patients (n = 19) experienced an overall response rate (ORR) of 31.6% (95% CI, 12.6%-56.6%), meeting the prespecified end point for the first stage of the trial. All responders achieved a partial response. Additionally, the stable disease rate was 15.18% (95% CI, 3.4%-39.6%), and the progressive disease rate was 52.6% (95% CI, 28.8%-75.5%).

“Our data further support previous pre-clinical evidence, suggesting that patients with HER2-positive, ER-negative or PAM50 non-luminal tumors might benefit from immunotherapy in combination with chemotherapy,” lead study author Eva Ciruelos Gil, MD, PhD, of Hospital 12 de Octubre, in Madrid, Spain, and colleagues, wrote in a poster presentation of the data.

Although antibody-drug conjugates (ADCs) such as fam-trastuzumab deruxtecan-nxki (Enhertu) have shifted the treatment landscape for patients with metastatic HER2-positive breast cancer, effective treatment options are still need for patients who progress on trastuzumab, pertuzumab (Perjeta), ado-trastuzumab emtansine (T-DM1; Kadcyla), trastuzumab deruxtecan, and/or other therapies. HER2-positive advanced breast cancer that is either ER-negative or PAM50 non-luminal disease is considered more immunogenic and linked with higher tumor-infiltrating lymphocytes and higher expression of immune-related genes.

Stage 1 of ATREZZO enrolled 19 patients, and stage 2 is expected to include 36 patients for a total enrollment of 55. The study includes female patients with advanced or metastatic HER2-positive breast cancer. Patients also need to have hormone receptor (HR)–negative or HR-positive/PAM50 non-luminal disease. PD-L1 status is measured through immunohistochemistry (IHC). Prior treatment with trastuzumab and other anti-HER2 ADCs—not limited to T-DM1—is required.2

In both parts of the single-arm trial with a Simon 2-stage design, patients are receiving 1200 mg of atezolizumab in combination with trastuzumab at 600 mg subcutaneously or 6mg/kg intravenously and vinorelbine at 25 mg/m² intravenously or 60 mg/m2 orally every 3 weeks.

The primary end point of the trial is ORR per RECIST v1.1 criteria. Secondary end points include ORR in the PD-L1–positive cohort, clinical benefit measured with clinical benefit rate at 6 months, progression-free survival (PFS), duration of response (DOR), time to response, and overall survival (OS), clinical benefit in patients with brain metastases, and safety/tolerability. PAM50 and 360 panel genes, DNA mutations, and circulating tumor DNA are serving as biomarkers of response.

In stage 1, patients had a median age of 58 years (range, 33-73). The majority of patients had an ECOG performance status of 1 (63.2%) and had HR-negative disease (68.4%). Patients had a HER2 status of IHC 2+ (amplified; (26.3%) or IHC 3+ (73.7%), and 31.6% of patients had advanced disease at first diagnosis. The mean time from advanced disease diagnosis to start of treatment data was 3.3 years (standard deviation, 2.8).

Furthermore, 21.1% of patients had a history of central nervous system (CNS) metastases, and 15.8% of patients underwent previous local treatment or procedures for their CNS, including stereotactic radiosurgery/stereotactic radiotherapy (5.3%) and whole brain radiotherapy (10.5%). Ninety percent of patients did not have visceral disease.

Notably, 63.2% of patients underwent previous treatment for early breast cancer, including antineoplastic agents (63.2%) and endocrine therapy (31.6%). Patients received a median of 3 (range, 1-4) prior lines of therapy for advanced disease.

Regarding safety, 31.6% of patients experienced grade 3 or higher treatment-emergent adverse effects (TRAEs), including 26.3% of patients with grade 3 TEAEs and 10.5% with grade 4 TEAEs.

The most common grade 3 or higher TEAEs included neutropenia (21.1%), fatigue (5.3%), and acute kidney injury (5.3%).

References

  1. Ciruelos E, Tolosa P, Salvador Bofill FJ, et al. Atrezzo trial (SOLTI-1907) a phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC): interim analysis. Presented at: 2023 ESMO Breast Cancer Annual Congress; May 11-13, 2023; Berlin, Germany. Abstract 197P.
  2. Study with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive advanced/metastatic breast cancer (ATREZZO). ClinicalTrials.gov. Updated April 14, 2023. Accessed May 30, 2023. https://clinicaltrials.gov/ct2/show/NCT04759248
Related Videos
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Nicholas P. McAndrew, MD, MSCE, University of California, Los Angeles Health
Sarah Sammons, MD
Sarah Sammons, MD
Maria Hafez, MD
Nicholas P. McAndrew, MD, MSCE
Nicholas P. McAndrew, MD, MSCE